Extracorporeal Magnetotransduction Therapy (EMTT) Clinical Evidence

Clinical governance statement

All treatments undertaken by MansMatters (Shockwave Clinics Ltd) are subject to clinical review before they are introduced into practice and at regular intervals thereafter. This review considers the safety profile of each intervention, including contraindications and adverse effects as specified in the manufacturer’s instructions for use or the Summary of Product Characteristics; the regulatory status of each medical device and medicinal product; the position of current UK and European clinical guidance, including the European Association of Urology (EAU), the National Institute for Health and Care Excellence (NICE) and the British Association of Urological Surgeons (BAUS); the qualifications and scope of practice of the treating clinicians; the stage and severity of the condition being treated; and the requirements for informed consent. Each patient is assessed individually, and treatment is offered only where it is clinically appropriate.

The basis of clinical evidence

Clinical evidence is derived from several sources, which carry different weight. Systematic reviews and meta-analyses pool the results of multiple studies and provide the highest level of evidence. Randomised controlled trials, including sham-controlled trials, compare a treatment against a control group under defined conditions. Prospective and retrospective cohort studies, published in peer-reviewed journals, describe outcomes in defined groups of patients over time, and the replication of results by independent research groups in different countries strengthens confidence in a finding. Laboratory and mechanistic studies explain how a treatment is thought to act. In-clinic observational studies and structured outcome audits record the results achieved in routine practice and contribute to the developing evidence base, particularly for newer and combined treatments. Long-term follow-up establishes the durability of results and the safety of a treatment over time.

The evidence relevant to this treatment is summarised below. All citations are hyperlinked to the original source.

Is it safe?

Extracorporeal Magnetotransduction Therapy (EMTT) is non-invasive and delivered without touching the skin. Our devices are made by Storz Medical AG and are CE-marked medical devices for musculoskeletal conditions, and we never use Extracorporeal Magnetotransduction Therapy (EMTT) on its own for Peyronie’s disease. As set out in the manufacturer’s operating manual, it isn’t suitable if you have a pacemaker or other electronic implant, or any implant not marked as MR Safe, including some penile implants. Mild discomfort or skin redness can occur and usually settles within a day.

What the evidence shows

Extracorporeal Magnetotransduction Therapy (EMTT) has a growing evidence base in musculoskeletal conditions, and we also use it in our clinics for joint, tendon and back problems. In a double-blind, placebo-controlled trial of 126 people with knee, shoulder and back conditions, it reduced pain and improved physical function at 12 weeks (Hollander et al. 2026), and a 2026 review of 28 studies reported no serious side effects and better results when it was combined with shockwave than with shockwave alone (Leyva Martínez et al. 2026). As a newer treatment for Peyronie’s disease, Extracorporeal Magnetotransduction Therapy (EMTT) is not yet included in guidelines. We include it because Peyronie’s disease involves processes it is thought to influence in other tissues, namely inflammation, scar tissue and blood flow, and because the combination evidence suggests it may add to the effect of Focused Shockwave Therapy (fSWT). For Peyronie’s disease, we only use it alongside Focused Shockwave Therapy (fSWT), and we are auditing our results.

Guidelines and regulation

Extracorporeal Magnetotransduction Therapy (EMTT) is delivered using CE-marked devices made by Storz Medical (operating manual), in a clinic registered with the Care Quality Commission. Our clinicians decide on an individual basis whether it is appropriate for each patient.

Independent research

Research on Extracorporeal Magnetotransduction Therapy (EMTT) has been published in peer-reviewed journals, mainly by university teams in Germany (Hollander et al. 2026), and independently reviewed by researchers in Mexico (Leyva Martínez et al. 2026). In the main placebo-controlled trial, the manufacturer, Storz Medical, supplied the placebo device and one author had received a lecture fee from the company, both of which are declared in the paper.

How Extracorporeal Magnetotransduction Therapy (EMTT) compares

In musculoskeletal conditions, Extracorporeal Magnetotransduction Therapy (EMTT) reduced pain by about 2 points on a 0–10 scale more than placebo at 12 weeks (Hollander et al. 2026). For Peyronie’s disease, we use it to complement treatments with stronger evidence: Focused Shockwave Therapy (fSWT) for pain, and traction or vacuum devices for curvature (EAU guidelines).

How Extracorporeal Magnetotransduction Therapy (EMTT) is thought to work

Extracorporeal Magnetotransduction Therapy (EMTT) uses high-energy pulsed magnetic fields that pass through tissue without touching the skin. Laboratory research suggests these may stimulate cell activity and tissue remodelling (Mancini et al. 2025), and clinical studies in musculoskeletal conditions have shown reduced pain (Hollander et al. 2026).

Long-term results and our experience

Published studies of Extracorporeal Magnetotransduction Therapy (EMTT) in musculoskeletal conditions have followed patients for around three months (Hollander et al. 2026). We have used Extracorporeal Magnetotransduction Therapy (EMTT) alongside Focused Shockwave Therapy (fSWT) for men with Peyronie’s disease for five years without serious side effects, and we are now recording outcomes for every patient so that we can report its long-term results.

Who is most likely to benefit

The main trial of Extracorporeal Magnetotransduction Therapy (EMTT) involved adults with an average age of about 60 with joint and back conditions (Hollander et al. 2026), a similar age to many men with Peyronie’s disease (Li et al. 2024). We consider it for men having Focused Shockwave Therapy (fSWT) who have no contraindications, and our outcome audit will help show which men benefit most.

Your choice

Extracorporeal Magnetotransduction Therapy (EMTT) is an optional part of your programme. Your clinician will talk you through what it involves and the current evidence, and help you decide whether it is right for you.